📊 BCAB Key Takeaways
Investment Thesis
BioAtla is a pre-revenue biopharmaceutical company with severely deteriorated financial condition, negative stockholders' equity of -$31.2M, and burning $40.3M in operating cash annually with only $8.3M in cash reserves. The company faces imminent solvency risk without significant capital infusion or revenue generation, making it unsuitable for risk-averse investors.
BCAB Strengths
- Recent improvement in net loss (-49.8M vs -87.1M prior year represents 43.5% reduction)
- Modest cash position of $8.3M provides short-term runway
- Active insider trading activity (7 Form 4 filings) suggests ongoing management engagement
BCAB Risks
- Negative stockholders' equity of -$31.2M indicates liabilities exceed assets by $31.2M
- Zero revenue with $50M operating losses indicates product development stage with no commercialization
- Critical cash burn rate of $40.3M annually against $8.3M cash reserve means approximately 2.5 months of runway
- Current ratio of 0.54x demonstrates severe liquidity crisis - current liabilities exceed current assets
- ROA of -313.2% reflects massive asset depletion relative to losses
Key Metrics to Watch
- Cash runway and timing of next capital raise requirement
- Revenue achievement and clinical trial advancement milestones
- Monthly cash burn rate trend and operating expense control
BCAB Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BCAB Profitability Ratios
BCAB vs Healthcare Sector
How BioAtla, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BCAB Balance Sheet & Liquidity
BCAB 5-Year Financial Trend
5-Year Trend Summary: BioAtla, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.58 indicates the company is currently unprofitable.
BCAB Growth Metrics (YoY)
BCAB Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | N/A | -$25.8M | $-0.69 |
| Q2 2023 | N/A | -$28.9M | $-0.75 |
| Q1 2023 | N/A | -$24.3M | $-0.58 |
| Q3 2022 | N/A | -$22.9M | $-0.68 |
| Q2 2022 | N/A | -$28.9M | $-0.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BCAB Capital Allocation
BCAB SEC Filings
Access official SEC EDGAR filings for BioAtla, Inc. (CIK: 0001826892)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BCAB
What is the AI rating for BCAB?
BioAtla, Inc. (BCAB) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCAB's key strengths?
Recent improvement in net loss (-49.8M vs -87.1M prior year represents 43.5% reduction). Modest cash position of $8.3M provides short-term runway.
What are the risks of investing in BCAB?
Negative stockholders' equity of -$31.2M indicates liabilities exceed assets by $31.2M. Zero revenue with $50M operating losses indicates product development stage with no commercialization.
What is BCAB's revenue and growth?
BioAtla, Inc. reported revenue of $0.0.
Does BCAB pay dividends?
BioAtla, Inc. does not currently pay dividends.
Where can I find BCAB SEC filings?
Official SEC filings for BioAtla, Inc. (CIK: 0001826892) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCAB's EPS?
BioAtla, Inc. has a diluted EPS of $-0.85.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.